Interview with Professor Michael Hoelscher, LMU Klinikum on Breakthroughs in Combatting Drug-Resistant Tuberculosis
BioM is proud to spotlight a recent interview with Prof. Michael Hoelscher, one of the initiators and consortia leads of the Pandemic Alliance Munich (PAM), which BioM coordinates. Featured in the LMU Magazine, the interview titled “Der Kampf gegen resistente Tuberkulose” (“The Fight Against Resistant Tuberculosis”) delves into Prof. Hoelscher’s innovative work developing a new medication aimed at tackling multi-drug-resistant tuberculosis (TB).
Professor Michael Hoelscher is an infectious disease physician and Director of the Tropical Institute at the Ludwig-Maximilians-University of Munich, and he also leads the Fraunhofer site for Immunology, Infection and Pandemic Research (IMTP) in Munich-Penzberg. He discusses how his research could provide a vital building block in the fight against resistant strains of TB.
To learn more about his insights and the promising developments in TB treatment, read the full interview in LMU Magazine:
The fight against resistant tuberculosis.
About Pandemic Alliance Munich (PAM)
The Pandemic Alliance Munich (PAM) is an initiative dedicated to preparing for future pandemic and health threats. It connects stakeholders from research institutions, clinical practice, SMEs, and industry to pool interdisciplinary expertise and accelerate innovation.
PAM aims to strengthen the scientific, technological, and organizational foundations needed for a rapid and coordinated response to infectious disease outbreaks through close cross-sector collaboration and networking. The focus spans the entire pandemic lifecycle — from prevention, detection, and diagnostics to therapeutic development and clinical as well as structural implementation.